Articles Tagged With: intracerebral
-
Long-Term Outcome in Patients with Intracerebral and Intraventricular Hemorrhage
Intracerebral hemorrhage continues to be a major cause of mortality and long-term disability. Early in the course of this severe disease prognosis is based on early characteristics, and care may be withdrawn at an early stage. The natural history and long-term recovery of survivors is uncertain because of withdrawal of care at an early time, resulting in a “self-fulfilling prophecy.”
-
Tranexamic Acid in Patients with Intracerebral Hemorrhage Does Not Improve Outcomes
Primary intracerebral hemorrhage is a major cause of severe neurological disability and carries a high rate of death. Tranexamic acid was tested in a study of 2,325 patients with intracerebral hemorrhage within eight hours of symptom onset, but did not significantly improve neurological outcome.
-
Management of Nontraumatic Intracranial Emergencies: A Clinical Update
This article attempts to provide evidence-based, practical guidelines to the frontline clinician in the nontrauma intensive care setting.
-
Clinical Outcomes After Oral Anticoagulant-Associated Intracerebral Hematoma
In this meta-analysis of multiple observational studies, clinical outcomes after oral anticoagulant-associated intracerebral hematoma were similar for those associated with vitamin K antagonists or the new class of direct oral anticoagulants.
-
Oral Anticoagulant-associated ICH
Intracerebral hemorrhage is the most dangerous and feared complication of oral anticoagulation and leads to a high mortality. Debate continues about the relative risk of hemorrhage with two classes of oral anticoagulants.
-
Subarachnoid Hemorrhage and Intracranial Hemorrhage
Time is of the essence in management of intracranial hemorrhage and subarachnoid hemorrhage. The longer it takes to make the diagnosis and initiate treatment, whether it is surgical intervention or simply aggressive primary stabilization, the greater the risk to the patient regarding both morbidity and mortality.
-
Idarucizumab: A Promising New Drug that Reverses the Anticoagulant Effects of Dabigatran
A recent study found that idarucizumab rapidly reverses the effects of dabigatran and is likely to have important clinical benefits for patients with intracerebral hemorrhage and other disease processes in which reversal of anticoagulation is important.